pharmaphorum

MAY 13, 2021

The first UK patient has enrolled on Pfizer’s phase 3 trial for its Duchenne muscular dystrophy (DMD) gene therapy. The first patient was recruited in The Newcastle upon Tyne Hospitals NHS Foundation Trust, one of three UK sites for the clinical trial and part of 55 globally, across 15 countries.

Gene Therapy 102

Gene Therapy Gene Trials Protein 102

pharmaphorum

JANUARY 13, 2022

Sanofi has joined a growing list of drugmakers going after alpha-synuclein targeting drugs for Parkinson’s disease, licensing a bispecific antibody from South Korea’s ABL Bio in a deal that could be worth more than $1 billion. The post Sanofi places $75m bet with ABL on popular Parkinson’s drug target appeared first on.

Antibody 98

Antibody Drugs Protein Licensing 98

The Pharma Data

NOVEMBER 30, 2020

(Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today provided an update on its COVID-19 vaccine program. pivotal Phase 3 trial update. Novavax completed enrollment of 15,000 participants in a pivotal Phase 3 clinical trial being conducted in the U.K.

Clinical Development 52

Clinical Development Vaccination Vaccine Development 52

Pharmaceutical Technology

FEBRUARY 20, 2023

ABN-401 is under clinical development by Abion and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. The drug candidate is a triazolopyrazine derivative. Buy the report here.

Protein 100

Protein Clinical Trials Clinical Trials Drugs 100

Pharmaceutical Technology

FEBRUARY 19, 2023

STRO-002 is under clinical development by Sutro Biopharma and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Refractory Acute Myeloid Leukemia have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. Buy the report here.

Antibody 100

Antibody Protein Clinical Development Manufacturing 100

Pharmaceutical Technology

JUNE 6, 2023

According to Globaldata, it is involved in 1 clinical trial, which is ongoing. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). The drug candidate is administered by intravenous route.

RNA 100

RNA Protein Antibody Vaccination 100

Pharmaceutical Technology

MARCH 2, 2023

Povetacicept is under clinical development by Alpine Immune Sciences and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData, Phase I drugs for Systemic Lupus Erythematosus have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. Buy the report here.

Protein 100

Protein Engineer Clinical Trials Clinical Trials 100

Drug Discovery World

JANUARY 15, 2024

Amgen and NVIDIA Amgen has announced plans to advance drug discovery using NVIDIA’s DGX SuperPOD-powered insights from human datasets. Chiesi and Oak Hill Bio Chiesi Group and Oak Hill Bio have entered a collaboration to develop OHB-607, a clinical-stage investigational drug candidate to treat complications of extremely premature birth.

Drugs 57

Drugs Licensing Licensing Protein 57

XTalks

JANUARY 23, 2024

Among these, rare pediatric diseases present unique challenges and opportunities for rare disease drug development. Pediatric growth hormone deficiency (PGHD) is one such condition, affecting a child’s growth and development.

Development 72

Development Hormones Drugs Trials 72

Pharmaceutical Technology

MAY 31, 2023

ATRN-119 is under clinical development by Aprea Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. The drug candidate is administered through oral route.

Production 100

Production Clinical Trials Clinical Trials Development 100

Drug Discovery World

JANUARY 6, 2023

ISA103 was developed using the company’s Synthetic Long Peptide (SLP) technology, designed to fully harness and direct the body’s defense mechanisms towards fighting the disease. It contains multiple long peptides spanning the most immunogenic regions of the PRAME protein. . A total of 90 patients will be enrolled in the trial. .

Trials 52

Trials Containment Protein Clinical Development 52

Pharmaceutical Technology

MARCH 23, 2023

Seagen specialises in developing antibody-drug conjugates (ADCs) which will complement Pfizer’s oncology portfolio. Seagen will maintain its operations in the Seattle area and will leverage Pfizer’s protein-engineering capabilities to develop next-generation biologics.

Licensing 147

Licensing Licensing Sales Trials 147

pharmaphorum

NOVEMBER 3, 2020

Regulatory reviews of Biogen’s Alzheimer’s drug aducanumab are now ongoing on both sides of the Atlantic, but debate is still ongoing about whether the data behind the drug is strong enough to support approval.

Trials 52

Trials Drugs Clinical Trials Clinical Trials 52

Pharmaceutical Technology

FEBRUARY 9, 2023

Buntanetap tartrate is under clinical development by Annovis Bio and currently in Phase III for Parkinson’s Disease. According to GlobalData, Phase III drugs for Parkinson’s Disease have a 46% phase transition success rate (PTSR) indication benchmark for progressing into Filing rejected/Withdrawn.

Clinical Trials 100

Clinical Trials Clinical Trials Drugs Development 100

Pharmaceutical Technology

FEBRUARY 9, 2023

Buntanetap tartrate is under clinical development by Annovis Bio and currently in Phase III for Alzheimer’s Disease. According to GlobalData, Phase III drugs for Alzheimer’s Disease have a 9% phase transition success rate (PTSR) indication benchmark for progressing into Filing rejected/Withdrawn. Buy the report here.

Clinical Trials 100

Clinical Trials Clinical Trials Drugs Development 100

Drug Discovery World

MARCH 24, 2023

Efti As a first-in-class soluble LAG-3 protein targeting MHC Class II ligands on antigen-presenting cells (APC), efti is positioned to improve clinical outcomes from standard-of-care chemotherapy. Its activation of APCs (e.g., The first patient is expected to be enrolled early in the second quarter of the 2023 calendar year.

Trials 52

Trials Immune Response HR Clinical Development 52

pharmaphorum

APRIL 28, 2022

OMass Therapeutics has raised an impressive $100 million in a Series B financing that is said to be the largest ever for a UK biotech focusing on small-molecule drug development. Robinson is OMass’ founder and scientific advisor.

Protein 105

Protein Drugs Development Clinical Trials 105

Drug Discovery World

AUGUST 12, 2022

Pfizer has launched a Phase III clinical trial of a vaccine to protect people against Lyme disease, in collaboration with pharmaceutical company Valneva. . The trial will enrol up to 6,000 participants aged five years and older and will be conducted across 50 sites where Lyme disease is highly endemic. Official comments .

Vaccination 52

Vaccination Vaccine Trials Bacteria 52

Drug Discovery World

JUNE 1, 2023

Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker 1. According to NCBI, most of the ADCs developed so far are for use in the treatment of cancer, but there is plenty of potential for using ADCs to treat other diseases 1.

Antibody 98

Antibody Marketing Drugs Licensing 98

Pharmaceutical Technology

MAY 31, 2023

Sym-021 is under clinical development by Les Laboratoires Servier and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. It is developed based on sympress platform technology.

Generic Drugs 100

Generic Drugs Hormones Manufacturing Development 100

pharmaphorum

MAY 30, 2022

For decades, RAS has existed as an elusive therapeutic target, and drugging this high-value oncogene was deemed impossible. Despite this, the first-ever FDA-approved KRAS G12C inhibitor has demonstrated that RAS is in fact druggable and that drugging this protein unlocks a world of successful therapeutic interventions.

Development 52

Development Drugs FDA Approval Clinical Trials 52

Drug Discovery World

JANUARY 19, 2023

A pilot Phase IIa clinical trial evaluating Abionyx Pharma’s CER-001 as a treatment for septic patients at high risk of developing acute kidney injury (AKI) has met its primary endpoint. million related deaths globally. “The trial shows promising positive results across a variety of primary and secondary endpoints.

Drugs 52

Drugs Trials Clinical Trials Clinical Trials 52

Pharmaceutical Technology

JUNE 5, 2023

BI-765063 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Hypopharyngeal Cancer. According to GlobalData, Phase I drugs for Hypopharyngeal Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase I. Buy the report here.

Production 100

Production Manufacturing Drugs Clinical Trials 100

Roots Analysis

FEBRUARY 27, 2024

On November 1, 2019, Avacta Group and ADC Therapeutics have announced a collaboration agreement for the development of novel drug candidates. The firm also has the right to obtain exclusive licenses to the Affimer proteins for clinical development and commercialization.

Antibody 52

Antibody Licensing Licensing Contract Manufacturing 52

Pharmaceutical Technology

FEBRUARY 24, 2023

ACE-1334 is under clinical development by Merck and currently in Phase I for Lung Disease. According to GlobalData, Phase I drugs for Lung Disease have a 92% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. It is developed based on protein engineering platform.

Production 100

Production Vaccination Vaccine Engineer 100

Pharmaceutical Technology

JUNE 10, 2023

RT-002 is under clinical development by Revance Therapeutics and currently in Phase II for Upper Limb Muscle Spasticity. According to GlobalData, Phase II drugs for Upper Limb Muscle Spasticity does not have sufficient historical data to build an indication benchmark PTSR for Phase II. Buy the report here.

Development 130

Development Drugs Clinical Trials Clinical Trials 130

Pharmaceutical Technology

JUNE 10, 2023

RT-002 is under clinical development by Revance Therapeutics and currently in Phase II for Upper Limb Muscle Spasticity. According to GlobalData, Phase II drugs for Upper Limb Muscle Spasticity does not have sufficient historical data to build an indication benchmark PTSR for Phase II. Buy the report here.

Development 130

Development Drugs Clinical Trials Clinical Trials 130

Delveinsight

AUGUST 13, 2020

Researchers call out Gilead over the diversity of remdesivir trials. Researchers have challenged the sponsors of COVID-19 clinical trials to run more diverse studies. The data hint approved COVID-19 drugs will be used extensively in Black, Latinx, and Native Americans. F2G raises USD 60.8 F2G has raised USD 60.8

Trials 52

Trials Research Drugs Protein 52

Pharmaceutical Technology

MARCH 1, 2023

Nedisertib is under clinical development by Merck and currently in Phase I for Neuroendocrine Tumors. According to GlobalData, Phase I drugs for Neuroendocrine Tumors have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. Buy the report here. It is a new chemical entity.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

MARCH 1, 2023

Nedisertib is under clinical development by Merck and currently in Phase I for Head And Neck Cancer Squamous Cell Carcinoma. According to GlobalData, Phase I drugs for Head And Neck Cancer Squamous Cell Carcinoma have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Drug Discovery World

MARCH 26, 2024

DDW’s Megan Thomas caught up with Oliver Rausch, Chief Scientific Officer at Storm Therapeutics, following the ESMO Targeted Anticancer Therapies Congress 2024, a global meeting focusing on promising new anticancer targets and agents, focusing on those in early phase clinical development.

RNA 62

RNA In-Vivo In-Vitro DNA 62

Pharmaceutical Technology

FEBRUARY 26, 2023

CUE-102 is under clinical development by Cue Biopharma and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase I drugs for Metastatic Colorectal Cancer have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. Buy the report here.

Drugs 100

Drugs Clinical Trials Clinical Trials Development 100

Pharmaceutical Technology

FEBRUARY 26, 2023

CUE-102 is under clinical development by Cue Biopharma and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData, Phase I drugs for Gastroesophageal (GE) Junction Carcinomas have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II.

Drugs 100

Drugs Clinical Trials Clinical Trials Development 100

The Pharma Data

JULY 22, 2021

(NYSE: PFE) today announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The companies will equally share worldwide development costs, commercialization expenses, and profits. Chief Executive Officer at Arvinas.

Protein 52

Protein Development HR Hormones 52

pharmaphorum

APRIL 19, 2022

Just days after dosing its first patient in a Duchenne muscular dystrophy trial, US biotech PepGen has pushed the button on an initial public offering (IPO). Once there, they disrupt the expression of RNA coding for disease-associated proteins. Once there, they disrupt the expression of RNA coding for disease-associated proteins.

Protein 105

Protein RNA Sales Production 105

XTalks

JULY 17, 2023

In a significant development, Astellas Pharma announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) had accepted their applications for Priority Review and Marketing Authorization respectively for zolbetuximab. In both trials, approximately 38 percent of the screened patients had CLDN18.2-positive

Clinical Trials 95

Clinical Trials Clinical Trials Trials Antibody 95

XTalks

APRIL 11, 2024

RELATED ON-DEMAND XTALKS WEBINAR: Leveraging Digital Biomarkers to Generate Real-World Physiological and Behavioral Data in CNS Clinical Studies Register for this free webinar to learn about an AI-based, multi-domain digital biomarker platform designed to provide objective, diverse and home-based patient data collection in CNS clinical trials.

Clinical Trials 110

Clinical Trials Clinical Trials Development Clinical Development 110